Answer first: Supplementary Protection Certificates (SPCs) extend patent protection for authorised medicinal products but present complex legal challenges. Recent developments and CJEU rulings continue to influence SPC requirements and strategies. J A Kemp LLP’s webinar provides expert guidance on adapting patent drafting, filing,…
Patents context for IP teams
Supplementary Protection Certificates (SPCs) serve as a crucial mechanism for extending patent protection for authorised human and veterinary medicinal products within Europe. Despite the SPC Regulation outlining only four fundamental criteria for grant, each has been the subject of extensive legal debate and numerous referrals to the Court of Justice of the European Union (CJEU).
The SPC landscape remains intricate and rapidly evolving, shaped by ongoing legal and political developments that influence the interpretation of these core requirements. This dynamic environment demands careful attention from patent practitioners and stakeholders involved in medicinal product protection.
Key takeaways for Supplementary Protection Certificates Europe
- Confirm how the development affects patents ownership, enforcement, licensing, or portfolio records.
- Separate confirmed facts from legal interpretation before advising business teams.
- Map deadlines, affected assets, contracts, and evidence files to the responsible internal owner.
- Use the issue as a prompt for monitoring, filing strategy, dispute preparation, or member education.
Practical analysis
In response to these challenges, J A Kemp LLP’s experienced SPC attorneys recently conducted a webinar delivering a practical update on the latest developments affecting SPC strategy across Europe and the United Kingdom. Drawing on their extensive experience prosecuting SPCs in multiple jurisdictions, the team highlighted critical considerations for patent portfolio preparation and management to maximize the advantages of the SPC system.
The session emphasized not only recent changes but also their practical implications for patent drafting, filing strategies, ownership planning, and managing third-party risks. These insights are essential for those overseeing existing SPC portfolios or planning future protection for medicinal products in European markets.
J A Kemp LLP advises clients globally, including in the USA and Europe, on UK and European patent practice. The firm represents clients before the European Patent Office, UK Intellectual Property Office, and the Unified Patent Court. Their expertise spans a broad range of technologies, including biotechnology, life sciences, pharmaceuticals, software, IT, chemistry, electronics, and engineering.
The firm’s guidance underscores the importance of adapting SPC strategies to a shifting legal framework, ensuring robust protection for medicinal products amid evolving regulatory interpretations.
This overview serves as a general guide to SPC-related matters. For specific circumstances, specialist legal advice is recommended to navigate the complexities of SPC applications and enforcement effectively.
As the SPC regulatory environment continues to develop, practitioners and rights holders must remain vigilant and proactive in managing their patent portfolios to leverage SPC protections fully.
Related IIPLA reading
Navigating Supplementary Protection Certificates in Europe: Key Updates and Strategic Insights Supplementary Protection Certificates (SPCs) extend patent protection for authorised medicinal products but present complex legal challenges. Recent developments and CJEU rulings continue to influence SPC requirements a... Read the full IIPLA blog post: https://iipla.org/blog/navigating-supplementary-protection-certificates-in-europe-key-updates-and-strategic-insights